Insulin resistance, prediabetes, and type 2 diabetes are related. They often overlap, and they sometimes occur in sequence, but moving from one to the next is not automatic. The three are defined in fundamentally different ways. Insulin resistance is a physiological state: cells respond less than expected to insulin. It has no standardized routine clinical cutoff, so it is usually inferred rather than measured directly in ordinary care.
Prediabetes and type 2 diabetes, by contrast, are diagnostic categories defined entirely by blood glucose or A1C values crossing specific thresholds. That difference matters. A person can be insulin resistant with normal glucose results, and a person can meet the numeric criteria for prediabetes without ever having had insulin resistance measured.
How the three relate to each other
Insulin resistance, prediabetes, and type 2 diabetes are best understood as three related but separately defined states. One often precedes the next: insulin resistance first, then glucose values in the prediabetes range, then glucose values in the diabetes range. That order is common enough to be worth understanding, but each step is possible rather than inevitable. The National Institute of Diabetes and Digestive and Kidney Diseases states plainly that not everyone with prediabetes goes on to develop type 2 diabetes (NIDDK).
Insulin resistance can exist while conventional glucose measures remain normal, because the pancreas can release more insulin to keep glucose in range. Prediabetes is diagnosed when a glucose or A1C result reaches an intermediate threshold set by the American Diabetes Association, above normal but below the diabetes range (ADA 2026 Standards of Care, Section 2). Type 2 diabetes is diagnosed when glucose or A1C reaches the higher diabetes threshold, typically when insulin secretion is no longer adequate relative to insulin resistance or metabolic demand (ADA 2026 Standards of Care, Section 2).
If your lab results show prediabetes, it means your blood glucose is higher than normal and the risk of developing type 2 diabetes is increased, but it does not mean type 2 diabetes will necessarily develop.
The three conditions, compared
The clearest way to separate insulin resistance, prediabetes, and type 2 diabetes is to look at how each one is identified. Insulin resistance is a physiological description without a standardized routine diagnostic number. Prediabetes and type 2 diabetes are defined by specific glucose and A1C values. That asymmetry explains most of the confusion between the three terms.
| Insulin resistance | Prediabetes | Type 2 diabetes | |
|---|---|---|---|
| What it is | Reduced biological response of cells to insulin | Glucose or A1C above normal but below diabetes thresholds | Chronic hyperglycemia from beta-cell insulin secretion inadequate relative to metabolic demand, frequently against a background of insulin resistance |
| What contributes to it | Multiple contributors | Often occurs alongside insulin resistance and beta-cell dysfunction, but is not synonymous with insulin resistance | Insufficient insulin secretion relative to demand, commonly with insulin resistance |
| How it is identified | No standardized routine clinical threshold | ADA glucose or A1C criteria (ADA 2026) | ADA glucose or A1C criteria (ADA 2026) |
| Symptoms | Usually absent | Often absent | Symptoms of hyperglycemia may occur, such as increased urination, increased thirst, or unexpected weight loss (ADA 2026) |
| Can it improve? | Yes | Yes, glucose levels can return below the prediabetes range | Yes, glucose levels can return below the diabetes range |
The numeric criteria for the two diagnostic categories are set by the American Diabetes Association.
| Measure | Prediabetes | Type 2 diabetes |
|---|---|---|
| A1C | 5.7%–6.4% (39–47 mmol/mol) | ≥6.5% (≥48 mmol/mol) |
| Fasting plasma glucose | 100–125 mg/dL (5.6–6.9 mmol/L) | ≥126 mg/dL (≥7.0 mmol/L) |
| 2-hour plasma glucose, 75-g OGTT | 140–199 mg/dL (7.8–11.0 mmol/L) | ≥200 mg/dL (≥11.1 mmol/L) |
Source: American Diabetes Association Professional Practice Committee, 2026.
Notice what is missing from that table: a row for insulin resistance. There is no equivalent routine cutoff, which is why insulin resistance is often described rather than diagnosed, and why a normal glucose panel does not by itself rule it out.
Where each one sits
Insulin resistance
Insulin resistance can be present while conventional glucose measures remain normal. The reason is compensation: when cells respond less to insulin, the pancreas can increase insulin secretion, and glucose may stay within the normal range as a result. Because of this, insulin resistance often exists before any glucose-based abnormality appears (NIDDK).
Two research studies illustrate how far this can go. In young, lean, normoglycemic adult offspring of parents with type 2 diabetes, Petersen and colleagues found approximately 60% lower insulin-stimulated muscle glucose uptake and approximately 80% higher intramyocellular lipid compared with matched control participants (Petersen et al. 2004). In a similar population of insulin-resistant offspring of parents with type 2 diabetes, Morino and colleagues reported reduced mitochondrial density and increased IRS-1 serine phosphorylation in muscle (Morino et al. 2005).
These were cross-sectional studies in a selected, family-history-enriched population. They establish that marked insulin resistance can coexist with normal glucose tolerance. They do not establish who will go on to develop diabetes, or how quickly, and they should not be read that way. For a reader with normal glucose results who has been told insulin resistance may be present, the useful point is that the two findings are not contradictory. For more on what insulin resistance actually is, see our guide to what insulin resistance is.
Prediabetes
Prediabetes is a glycemic category, not a direct measurement of insulin resistance. Prediabetes often develops when the pancreas can no longer fully compensate for insulin resistance, so glucose begins to rise, but the diagnosis comes from the glucose or A1C result, not from a particular insulin level (ADA 2026 Standards of Care, Section 2).
The underlying physiology is heterogeneous. When cells resist insulin, the body often makes more insulin to compensate (Abdul-Ghani & DeFronzo 2021), but insulin output isn’t always high or rising in everyone with prediabetes. In many people whose glucose falls in the prediabetes range, the beta cells that make insulin are already struggling to keep up with demand. So two individuals can have the same glucose result yet considerably different insulin levels.
This is also why prediabetes and insulin resistance are not synonyms. Testing for insulin resistance is not required to diagnose prediabetes, and routine care generally does not include it; insulin resistance is more often assessed in research settings than measured directly in clinical practice (NIDDK). A prediabetes result tells you where glucose currently sits. It does not, on its own, quantify how insulin resistant a person is, and it does not determine what happens next.
Type 2 diabetes
Type 2 diabetes is classified by the American Diabetes Association as a nonautoimmune, progressive loss of adequate beta-cell insulin secretion, frequently occurring against a background of insulin resistance (ADA 2026 Standards of Care, Section 2). The diagnosis itself is made on glucose or A1C criteria, not on an insulin measurement.
The word “adequate” is doing important work in that definition. When glucose reaches the diabetes range, insulin supply is inadequate relative to what the body needs at that level of insulin resistance and metabolic demand. That is not the same as saying insulin levels are literally low. A person with type 2 diabetes may have insulin concentrations that are normal or even elevated in absolute terms, yet still insufficient for the demand placed on the beta cells.
This distinction matters when interpreting results. Type 2 diabetes is not defined by the pancreas shutting down, and a measured insulin level is not what separates type 2 diabetes from prediabetes. The separation is the glucose or A1C threshold.
What has held up, what hasn’t, and what remains disputed
Held up. Insulin resistance, prediabetes, and type 2 diabetes are distinct and differently defined: one is a physiological state without a standardized routine clinical threshold, and two are glycemic diagnostic categories with explicit numeric criteria (NIDDK; ADA 2026 Standards of Care). Insulin resistance can be present when glucose is normal, as measured in young, lean, normoglycemic offspring of parents with type 2 diabetes (Petersen et al. 2004; Morino et al. 2005). Insulin resistance can precede prediabetes, which raises the risk of type 2 diabetes without making progression inevitable; not everyone with prediabetes develops type 2 diabetes (NIDDK).
Hasn’t held up, or hasn’t yet. There is no fixed general timeline for progression from insulin resistance to prediabetes, or from prediabetes to type 2 diabetes. How fast, or whether, glucose moves from one range to the next depends on things that differ from person to person — the degree of insulin resistance, how well the beta cells compensate, age, genetics, lifestyle factors, and more (ADA 2026 Standards of Care). Progression is common in populations; it is not scheduled in individuals.
Disputed. The conventional model treats hyperinsulinemia as a consequence of insulin resistance, with the beta cells compensating for reduced insulin sensitivity, but the causal direction has been debated, including whether hyperinsulinemia may itself contribute to the development of insulin resistance (Abdul-Ghani & DeFronzo 2021; Xing & Chen 2022). This remains genuinely unsettled rather than quietly resolved; the relationship between hyperinsulinemia and insulin resistance is an active area of disagreement.
Frequently asked questions
Can you have prediabetes without insulin resistance?
Yes. A prediabetes diagnosis does not require demonstrated insulin resistance. Prediabetes is defined entirely by glucose or A1C criteria (ADA 2026 Standards of Care), and in ordinary clinical care insulin resistance is usually not measured directly at all, which means most people with prediabetes have never had it formally quantified (NIDDK).
That said, insulin resistance is common in prediabetes, and you should not read this as insulin resistance being rare or unimportant in that group. The physiology behind an intermediate glucose result varies: beta-cell dysfunction and insulin secretion that is inadequate relative to a person’s insulin sensitivity contribute in many people, alongside or independently of insulin resistance. So the honest answer is that prediabetes and insulin resistance overlap heavily but are established in different ways, and one does not automatically confirm the other.
Which is more serious, insulin resistance or prediabetes?
That comparison does not work well, because insulin resistance and prediabetes are not two positions on a single severity scale. Insulin resistance is a physiological state describing a reduced response to insulin, and it has no standardized routine clinical threshold that separates mild from severe in everyday practice (NIDDK). Prediabetes is a defined glycemic diagnosis based on specific glucose and A1C values (ADA 2026 Standards of Care), and it is associated with increased risk of type 2 diabetes and cardiovascular disease.
So you are comparing a description of how your body responds to insulin against a diagnostic category based on a number. Rather than ranking them, it is more accurate to note what each one tells you: insulin resistance describes a mechanism, prediabetes describes where your glucose currently sits and the risk associated with that position.
How long does it take insulin resistance to become type 2 diabetes?
It varies. Some people remain insulin resistant for long periods without ever meeting diabetes criteria. Some people with prediabetes do not progress to type 2 diabetes at all (NIDDK). Others move into the diabetes range more quickly. Progression is common enough to take seriously, but it is not automatic and it is not governed by a universal clock, which is why a specific number of years cannot honestly be given here.
The rate at which glucose changes, if it changes at all, varies with the degree of insulin resistance, how well the beta cells compensate, age, genetics, body-fat distribution, medications, lifestyle interventions, and other factors.
Can you develop type 2 diabetes without going through prediabetes?
Yes, in the sense that matters for how diagnoses are recorded. Prediabetes and type 2 diabetes are diagnostic categories, not mandatory biological waypoints. A person can be tested for the first time and have glucose or A1C already meeting the diabetes criteria, with no documented prediabetes diagnosis anywhere in their record (ADA 2026 Standards of Care).
This usually does not mean glucose jumped from normal to the diabetes range overnight. Prediabetes is captured only when testing happens to occur while glucose sits in the intermediate range. If no test was done during that window, the intermediate range simply was not measured. So the absence of a prior prediabetes diagnosis tells you about testing history, not necessarily about how glucose changed over time.
Conclusion
Insulin resistance, prediabetes, and type 2 diabetes are distinct concepts that frequently overlap. Insulin resistance can exist while glucose and A1C remain in the normal range, because increased insulin secretion may keep glucose in check. Prediabetes and type 2 diabetes are diagnosed by glucose and A1C thresholds, with type 2 diabetes reflecting insulin secretion inadequate relative to insulin resistance or metabolic demand.
Progression across these categories is common, but it is not inevitable, and not everyone with prediabetes develops type 2 diabetes. There is no universal clock governing how, or whether, one state becomes the next. Whether insulin resistance can improve is a separate question from where a current glucose result sits.
References
- National Institute of Diabetes and Digestive and Kidney Diseases. Insulin Resistance & Prediabetes. Current NIDDK health information page.
- American Diabetes Association Professional Practice Committee. Diagnosis and Classification of Diabetes: Standards of Care in Diabetes—2026. Diabetes Care. 2026;49(Supplement 1). doi:10.2337/dc26-S002.
- Petersen KF, Dufour S, Befroy D, Garcia R, Shulman GI. Impaired mitochondrial activity in the insulin-resistant offspring of patients with type 2 diabetes. New England Journal of Medicine. 2004;350(7):664-671. doi:10.1056/NEJMoa031314. PMID:14960743.
- Morino K, Petersen KF, Dufour S, et al. Reduced mitochondrial density and increased IRS-1 serine phosphorylation in muscle of insulin-resistant offspring of type 2 diabetic parents. Journal of Clinical Investigation. 2005;115(12):3587-3593. doi:10.1172/JCI25151. PMID:16284649.
- Abdul-Ghani M, DeFronzo RA. Insulin Resistance and Hyperinsulinemia: the Egg and the Chicken. Journal of Clinical Endocrinology & Metabolism. 2021;106(4). doi:10.1210/clinem/dgaa364. PMID:33522574.
- Xing J, Chen C. Hyperinsulinemia: beneficial or harmful or both on glucose homeostasis. American Journal of Physiology-Endocrinology and Metabolism. 2022;323(1). doi:10.1152/ajpendo.00441.2021. PMID:35635329.